“…In other studies, HER2 overexpression was defined as HER2 3+ in IHC and as HER2 2+ in IHC and specimens with amplified HER chromosome levels based on fluorescence in situ hybridization (FISH) or silver-enhanced in situ hybridization (SISH). HER2 overexpression rates ranged from 6 to 35% [8–12, 15–18, 20, 22, 28, 29]. IHC and FISH/SISH showed a concordance rate of HER2 expression to be 88.5–93.5% [11, 18, 25, 30, 31].…”
Section: Discussionmentioning
confidence: 99%
“…HER2 overexpression rates ranged from 6 to 35% [8–12, 15–18, 20, 22, 28, 29]. IHC and FISH/SISH showed a concordance rate of HER2 expression to be 88.5–93.5% [11, 18, 25, 30, 31]. The rates of specimens with HER2 2+ in IHC and amplified HER2 gene levels based on FISH (or SISH) were 4% [11], 7.7% [8], and 20% [9], respectively.…”
Section: Discussionmentioning
confidence: 99%
“…Kataoka et al [15] reported that HER2 overexpression was related to males, old age, and intestinal-type adenocarcinoma. Shen et al [18] claimed that HER2 expression was associated with sex, tumor location, histologic differentiation, and TNM stage. Begnami et al [19] reported that HER2 overexpression was related to the degree of tumor invasion, lymph node metastasis, and tumor pathologic stage.…”
Background
The purpose of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and clinicopathologic factors and overall survival rate in patients who underwent curative gastrectomy for gastric adenocarcinoma.
Methods
Among patients who underwent curative gastrectomy for gastric adenocarcinoma at Inje University Paik Hospital from January 2012 to December 2015, 782 patients underwent an immunohistochemical analysis to evaluate HER2 expression levels. Clinicopathologic records that were collected from a gastric cancer database were retrospectively reviewed to identify clinicopathologic factors and survival rates of the patients.
Results
HER2 overexpression was detected in 166 patients (21.2%). There was a statistically significant correlation between HER2 expression level and sex (
p
= 0.013), histologic differentiation (
p
< 0.001), Lauren classification (
p
< 0.001), and T pathologic stage (
p
= 0.022). There were no statistically significant relationships between HER2 expression level and overall 5-year survival rate (
p
= 0.775) and overall 5-year survival rate of gastric adenocarcinoma classified according to the TNM stage (stage I:
p
= 0.756, stage II:
p
= 0.571, stage III:
p
= 0.704). The HER2 expression level was not affected by the overall 5-year survival rate in the uni- and multivariate analyses.
Conclusions
In this study, the HER2 overexpression rate in gastric adenocarcinoma was 21.2% and was observed in well- and moderately differentiated types according to histologic differentiation, intestinal type according to the Lauren classification, male, and low T stage. There was no correlation between HER2 expression level and overall 5-year survival rate, and HER2 expression level was not associated with independent prognostic factors.
“…In other studies, HER2 overexpression was defined as HER2 3+ in IHC and as HER2 2+ in IHC and specimens with amplified HER chromosome levels based on fluorescence in situ hybridization (FISH) or silver-enhanced in situ hybridization (SISH). HER2 overexpression rates ranged from 6 to 35% [8–12, 15–18, 20, 22, 28, 29]. IHC and FISH/SISH showed a concordance rate of HER2 expression to be 88.5–93.5% [11, 18, 25, 30, 31].…”
Section: Discussionmentioning
confidence: 99%
“…HER2 overexpression rates ranged from 6 to 35% [8–12, 15–18, 20, 22, 28, 29]. IHC and FISH/SISH showed a concordance rate of HER2 expression to be 88.5–93.5% [11, 18, 25, 30, 31]. The rates of specimens with HER2 2+ in IHC and amplified HER2 gene levels based on FISH (or SISH) were 4% [11], 7.7% [8], and 20% [9], respectively.…”
Section: Discussionmentioning
confidence: 99%
“…Kataoka et al [15] reported that HER2 overexpression was related to males, old age, and intestinal-type adenocarcinoma. Shen et al [18] claimed that HER2 expression was associated with sex, tumor location, histologic differentiation, and TNM stage. Begnami et al [19] reported that HER2 overexpression was related to the degree of tumor invasion, lymph node metastasis, and tumor pathologic stage.…”
Background
The purpose of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and clinicopathologic factors and overall survival rate in patients who underwent curative gastrectomy for gastric adenocarcinoma.
Methods
Among patients who underwent curative gastrectomy for gastric adenocarcinoma at Inje University Paik Hospital from January 2012 to December 2015, 782 patients underwent an immunohistochemical analysis to evaluate HER2 expression levels. Clinicopathologic records that were collected from a gastric cancer database were retrospectively reviewed to identify clinicopathologic factors and survival rates of the patients.
Results
HER2 overexpression was detected in 166 patients (21.2%). There was a statistically significant correlation between HER2 expression level and sex (
p
= 0.013), histologic differentiation (
p
< 0.001), Lauren classification (
p
< 0.001), and T pathologic stage (
p
= 0.022). There were no statistically significant relationships between HER2 expression level and overall 5-year survival rate (
p
= 0.775) and overall 5-year survival rate of gastric adenocarcinoma classified according to the TNM stage (stage I:
p
= 0.756, stage II:
p
= 0.571, stage III:
p
= 0.704). The HER2 expression level was not affected by the overall 5-year survival rate in the uni- and multivariate analyses.
Conclusions
In this study, the HER2 overexpression rate in gastric adenocarcinoma was 21.2% and was observed in well- and moderately differentiated types according to histologic differentiation, intestinal type according to the Lauren classification, male, and low T stage. There was no correlation between HER2 expression level and overall 5-year survival rate, and HER2 expression level was not associated with independent prognostic factors.
“…In addition, patients with HER2 (+) gastric cancer showed an improved outcome with chemotherapy. The association of HER2 status with prognosis in a total of 1562 gastric cancer patients undergoing R0 resection was also investigated by Shen et al [17] They reported that there were no significant associations between HER2 status and DFS or OS in multivariate analysis. In our study, the incidence of HER2 positivity was 16%.…”
Section: Local Recurrences and Distant Metastasismentioning
OBJECTIVEOur purpose was to evaluate the prognostic or predictive importance of HER2 status in gastric cancer patients treated with postoperative chemoradiotherapy.
METHODSWe retrospectively analyzed the records of 49 gastric cancer patients treated with curative intent between April 2012 and January 2017; we also assessed the impact of HER2 status on prognosis and treatment outcomes.
RESULTSDuring a median follow-up period of 14.6 months (range, 4.0-56.97 months), two patients (4%) had local recurrence and 21 patients (43%) developed distant metastasis. We found no statistically significant difference in metastasis frequency rates between HER2 negative (−) and positive (+) patients. The median overall survival (OS) and disease-free survival (DFS) for the whole group were 24.9 and 24.2 months, respectively. Although there was no significant difference in OS and DFS according to HER2 status, there was a negative trend in OS (p=0.451) and DFS (p=0.633) in HER2 (+) patients.
CONCLUSIONAlthough our study did not demonstrate any statistically significant importance of HER2 status in gastric cancer patients treated with postoperative chemoradiotherapy, the median OS of 13 months in HER2 (+) patients and 24.9 months for HER2 (−) patients warranted randomized trials with larger cohorts.
“…In China, according to cancer statistics, the estimated incidence rate for GC was 679.1 per 100,000 people per year, and the mortality rate was ~498.0 per 100,000 people per year, while over 60% patients were in the advanced stage (2). Since the prognosis for GC patients is very poor, many molecular markers, including HER2, E-cadherin, EGFR, and KRAS have been evaluated as candidate prognostic factors for GC (3,4).…”
Abstract. The present study aimed to investigate the expression, clinical association, and prognosis of RecQ protein-like 4 (RECQL4) protein in human gastric cancers (GCs). The expression levels and prognostic value of RECQL4 were initially predicted by using bioinformatics. GC specimens and matched normal gastric tissues were evaluated by immunohistochemistry (IHC), and patient clinicopathological parameters and survival times were analyzed. Multivariate Cox analysis was used to determine the prognostic role of RECQL4 expression. The Oncomine database predicted that RECQL4 mRNA expression levels were significantly increased in GCs as compared with those in normal gastric tissues (P<0.05) and that patients with increased RECQL4 mRNA expression levels had significantly lower overall survival (OS) (P<0.001). The results of IHC showed that the positive rate of RECQL4 in the GC samples was significantly higher than that in the normal gastric mucosa specimens (P<0.05). RECQL4 expression was positively associated with depth of invasion and TNM (P<0.05). High RECQL4 expression in GC samples was significantly associated with poor OS (P=0.024). Positive RECQL4 expression, depth of invasion, lymphatic invasion, and TNM staging were independent factors for predicting worse OS rates by using multivariate analysis. Compared with expression levels in normal gastric tissues, RECQL4 was significantly overexpressed in GC samples, and increased RECQL4 expression was an independent predictor of poor prognosis in GC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.